Print PDF
Chad Landmon Discusses Cubist's Lawsuit Against Teva with Pharmawire
June 26, 2009

Cubist Pharmaceuticals, a Lexington, MA, based antibiotic company, could face problems with the planned sale of the company in the near term because of ongoing litigation and patent woes. Cubist is currently involved in a lawsuit with Teva over a generic version of the drug Cubicin, a drug used to treat Staphyloccus aureus, or MRSA. Teva filed suit on February 9, 2009 claiming that patents filed by Cubist are not infringed and/or invalid. Cubist has since filed a patent infringement lawsuit against Cubist. This lawsuit has  apparently raised questions with possible buyers about the validity of other Cubist patents. Chad Landmon, a partner in the  FDA and Biomedical  Practice  Groups at Axinn, discussed with Jacqueline Kwong of Pharmawire the likelihood of Cubist winning it’s case against Teva, saying that the fact that Cubist’s patent did not reissue until six years later, between the period of 2000-2006, suggests that there  may be  problems with the reissued patent.

The article, titled, “Cubist’s lawsuit against Teva keeps potential buyers wary, sources say,” was published by Pharmawire on June 26, 2009. Click here for a copy of the article:

Additional Documents:

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.